Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Kratz

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|October 1, 2004
Clinical pulmonary autograft valves: pathologic evidence of adaptive remodeling in the aortic siteElena Rabkin-Aikawa, Masanori Aikawa, Mark Farber, et al.
Cancer Management and Research|November 6, 2019
Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcomaLong Jiang, Bhairavi Tolani, Che-Chung Yeh, et al.
Neurology|December 31, 1997
Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study GroupE C Lai, K J Felice, B W Festoff, et al.
The Journal of Clinical Investigation|December 13, 2005
Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2Kush M Parmar, H Benjamin Larman, Guohao Dai, et al.
Scientific Reports|December 9, 2021
Genetic and immunologic features of recurrent stage I lung adenocarcinomaJohannes R Kratz, Jack Z Li, Jessica Tsui, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|May 1, 2013
Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancerJohannes R Kratz, Patrick T Tham, Michael S Mulvihill, et al.
Clinical Lung Cancer|June 25, 2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung CancerGavitt A Woodard, Sue X Wang, Johannes R Kratz, et al.
Clinical Lung Cancer|July 6, 2011
Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patientsJunichi Okamoto, Johannes R Kratz, Tomomi Hirata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 9, 2019
Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer StagingJohannes R Kratz, Greg J Haro, Nancy R Cook, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
The Journal of Thoracic and Cardiovascular Surgery|October 1, 2004
Clinical pulmonary autograft valves: pathologic evidence of adaptive remodeling in the aortic siteElena Rabkin-Aikawa, Masanori Aikawa, Mark Farber, et al.
Cancer Management and Research|November 6, 2019
Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcomaLong Jiang, Bhairavi Tolani, Che-Chung Yeh, et al.
Neurology|December 31, 1997
Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study GroupE C Lai, K J Felice, B W Festoff, et al.
The Journal of Clinical Investigation|December 13, 2005
Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2Kush M Parmar, H Benjamin Larman, Guohao Dai, et al.
Scientific Reports|December 9, 2021
Genetic and immunologic features of recurrent stage I lung adenocarcinomaJohannes R Kratz, Jack Z Li, Jessica Tsui, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|May 1, 2013
Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancerJohannes R Kratz, Patrick T Tham, Michael S Mulvihill, et al.
Clinical Lung Cancer|June 25, 2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung CancerGavitt A Woodard, Sue X Wang, Johannes R Kratz, et al.
Clinical Lung Cancer|July 6, 2011
Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patientsJunichi Okamoto, Johannes R Kratz, Tomomi Hirata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 9, 2019
Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer StagingJohannes R Kratz, Greg J Haro, Nancy R Cook, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Pageof 5